Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
Anti-Inflammatory Challenge in Schizophrenia
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT05823532
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-05-09
- Target Recruit Count
- 976
- Registration Number
- NCT05813860
Treatment and Fate in Fistulizing Crohn's Disease in a Pediatric Population
- Conditions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 40
- Registration Number
- NCT05759104
Precise Infliximab Exposure and Pharmacodynamic Control
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 180
- Registration Number
- NCT05660746
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Cleveland Clinic Children's Hospital, Cleveland, Ohio, United States
Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05552287
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
A Multicentered Prospective Cohort Study of Chinese IBD Patients
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05386290
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Safety of Reduced Infliximab Infusion Time
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 96
- Registration Number
- NCT05340764
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Rehab Werida
- Target Recruit Count
- 56
- Registration Number
- NCT05291039
- Locations
- 🇪🇬
Tropical Medicine department, Ain Shams University Hospitals., Cairo, Egypt
Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- IRCCS Burlo Garofolo
- Target Recruit Count
- 86
- Registration Number
- NCT05280405
- Locations
- 🇮🇹
Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy
SOLIDARITY Finland Plus Long-COVID
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Clinical Urology and Epidemiology Working Group
- Target Recruit Count
- 400
- Registration Number
- NCT05220280
- Locations
- 🇫🇮
University of Helsinki, Helsinki, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.